Harbin Gloria Pharmaceuticals Cash Flow-to-Debt Ratio
Harbin Gloria Pharmaceuticals cash flow-to-debt ratio. Harbin Gloria Pharmaceuticals (002437) has a Cash Flow-to-Debt Ratio of 0.21x as of September 2025, meaning its operating cash flow of CN¥182.89 Million could theoretically repay 0% of its total liabilities (CN¥852.18 Million) in one year. Check 002437 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Harbin Gloria Pharmaceuticals (2007–2025)
Cash flow-to-debt ratio of Harbin Gloria Pharmaceuticals from 2007 to 2025. Historical debt coverage capacity for Harbin Gloria Pharmaceuticals across 19 annual periods. Check how aggressively does Harbin Gloria Pharmaceuticals reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Harbin Gloria Pharmaceuticals Cash Flow-to-Debt Ratio by Year (2007–2025)
Harbin Gloria Pharmaceuticals cash flow-to-debt ratio by year from 2007 to 2025. Year-by-year debt coverage analysis for Harbin Gloria Pharmaceuticals. For the full cash flow conversion analysis, see 002437 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.33x | CN¥273.36 Million | CN¥825.00 Million | ▼ -31.3% |
| 2024 | 0.48x | CN¥410.94 Million | CN¥852.26 Million | ▲ +153.6% |
| 2023 | 0.19x | CN¥274.18 Million | CN¥1.44 Billion | ▲ +72.3% |
| 2022 | 0.11x | CN¥261.62 Million | CN¥2.37 Billion | ▲ +9.3% |
| 2021 | 0.10x | CN¥274.18 Million | CN¥2.72 Billion | ▲ +1943.0% |
| 2020 | 0.00x | CN¥12.76 Million | CN¥2.58 Billion | ▼ -96.1% |
| 2019 | 0.13x | CN¥610.37 Million | CN¥4.82 Billion | ▼ -44.6% |
| 2018 | 0.23x | CN¥1.16 Billion | CN¥5.08 Billion | ▲ +68.9% |
| 2017 | 0.14x | CN¥651.80 Million | CN¥4.81 Billion | ▼ -39.9% |
| 2016 | 0.23x | CN¥1.04 Billion | CN¥4.62 Billion | ▲ +55.4% |
| 2015 | 0.14x | CN¥702.05 Million | CN¥4.85 Billion | ▼ -60.9% |
| 2014 | 0.37x | CN¥674.04 Million | CN¥1.82 Billion | ▼ -62.0% |
| 2013 | 0.98x | CN¥453.02 Million | CN¥464.60 Million | ▼ -3.5% |
| 2012 | 1.01x | CN¥205.89 Million | CN¥203.79 Million | ▼ -9.7% |
| 2011 | 1.12x | CN¥128.61 Million | CN¥114.91 Million | ▼ -26.7% |
| 2010 | 1.53x | CN¥112.59 Million | CN¥73.73 Million | ▲ +38.5% |
| 2009 | 1.10x | CN¥170.82 Million | CN¥154.95 Million | ▲ +62.4% |
| 2008 | 0.68x | CN¥57.81 Million | CN¥85.17 Million | ▲ +0.2% |
| 2007 | 0.68x | CN¥52.26 Million | CN¥77.15 Million | — |